(Q43789987)

26 November 2017

title

Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV). (English)

1 reference

26 November 2017

0 references

8

Britta Wahren

1 reference

26 November 2017

6

Göran Bratt

1 reference

26 November 2017

author name string

Ann-Charlotte Boström

1

1 reference

26 November 2017

Bo Hejdeman

2

1 reference

26 November 2017

Reikei Matsuda

3

1 reference

26 November 2017

Malin Fredriksson

4

1 reference

26 November 2017

Eva-Lena Fredriksson

5

1 reference

26 November 2017

Eric Sandström

7

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

26 November 2017

1 reference

26 November 2017

volume

22

1 reference

26 November 2017

issue

13-14

1 reference

26 November 2017

page(s)

1683-1691

1 reference

Treatment of homosexual men infected with Entamoeba histolytica

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

CD4+ lymphocyte function with early human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Early T-helper cell defects in HIV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Impairment in T-lymphocyte responses during early infection with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Human immunodeficiency virus type 1- and cytomegalovirus-specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4(+) T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Skewed maturation of memory HIV-specific CD8 T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Active Immunization of Patients with HIV Infection: A Study of the Effect of VaxSyn, a Recombinant HIV Envelope Subunit Vaccine, on Progression of Immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Induction of specific T-cell responses in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Less is more? STI in acute and chronic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Structured treatment interruptions for the management of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Better preserved immune responses after immunization with rgp 160 in HIV-1 infected patients treated with highly active antiretroviral therapy than in untreated patients with similar CD4 levels during at 2 years' follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

HIV gp120 plus specific peptides are recognized in a similar manner to specific HLA plus peptide by HLA-restricted antigen-specific T-cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

inferred from DOI database lookup

7 January 2021

based on heuristic

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.049

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.09.049

1 reference

26 November 2017

1 reference